Senior Research Associate, Immunology
Xilio Therapeutics
Summary
Xilio is searching for a Senior Research Associate to join the Immunology group and help enable our exciting immuno-oncology pipeline. This opening serves as an excellent opportunity to contribute to novel therapies that have the potential to help cancer patients, while developing technical skills in a trailblazing IO-focused biotech.
Job description
Summary
Xilio is searching for a Senior Research Associate to join the Immunology group and help enable our exciting immuno-oncology pipeline. This opening serves as an excellent opportunity to contribute to novel therapies that have the potential to help cancer patients, while developing technical skills in a trailblazing IO-focused biotech.
The position will be based in Waltham, Massachusetts, and reports to an immunology group lead.
Job Responsibilities
- Work closely with colleagues in immunology, cell pharmacology, and the broader research organization to support Xilio's discovery and development programs.
- Design, and perform assays, analyze data with the appropriate statistical analyses and present results.
- Work as an integrated member of the research team to generate data supportive of ongoing drug discovery efforts.
- Contribute to key project team decisions and translational studies for development stage assets.
- Responsible for the management and organization of primary cell banks.
- Responsible for the management, organization and expansion of immortalized cell lines and primary T cells.
- Capture detailed experimental information in electronic lab notebook (ELN) entries.
- Regular participation and presentation of data and analyses at Immunology team, department meetings.
Skills, Qualifications, and Requirements
- BA with 2-4 years of post-graduate biotech/pharma experience or related subject OR MS with 1 year of industry experience
- Experience with primary mammalian cell culture and aseptic technique is desired
- Familiarity with the development and execution of immunological in vitro assays is preferred
- Experience with ELISA is desired
- Experience with single-color flow cytometry is preferred
- Goal oriented, organized, capable of working on multiple projects, and able to execute to timelines that meet company goals
- Willing to learn new techniques and skills
- Work well in a cross-functional team environment, both independently as well as be willing to help others
- Excellent verbal and written communication skills
Requirements
- BA with 2-4 years of post-graduate biotech/pharma experience or related subject OR MS with 1 year of industry experience
- Experience with primary mammalian cell culture and aseptic technique is desired
- Familiarity with the development and execution of immunological in vitro assays is preferred
- Experience with ELISA is desired
- Experience with single-color flow cytometry is preferred
- Goal oriented, organized, capable of working on multiple projects, and able to execute to timelines that meet company goals
- Willing to learn new techniques and skills
- Work well in a cross-functional team environment, both independently as well as be willing to help others
- Excellent verbal and written communication skills
Benefits
- Professional development courses
- Job-related training allowance
- Seminars & meetings
Company overview
Xilio Therapeutics is a clinical-stage biotechnology company based in Waltham, Massachusetts, focused on developing innovative tumor-activated immunotherapies for cancer treatment. Founded in 2016, the company leverages its proprietary technology platform to create therapies that are selectively activated within tumors while minimizing systemic toxicity. Xilio's approach involves engineering antibodies, cytokines, and chemokines to achieve targeted therapeutic activity, drawing inspiration from its name derived from the Latin term 'Ex Nihilo,' meaning creation or big-bang. The company is advancing a diverse pipeline including vilastobart (a masked anti-CTLA-4 therapy), efarindodekin alfa (a masked IL-12), and several masked T-cell engager programs targeting various solid tumors. Xilio has established strategic partnerships with major pharmaceutical companies and has raised significant funding to support its clinical development programs, with multiple candidates currently in Phase 1 and Phase 2 clinical trials.